Genetic profile identification in clinically localized prostate carcinoma.
OBJECTIVE
To confirm our previously obtained results, we genetically characterized prostate cancer from patients undergo radical prostatectomy in a retrospective study.


METHODS
Histological sections were evaluated for 106 patients treated with surgery from 1991 to 2004. With fluorescence in situ hybridization (FISH) method, the status of LPL (8p22), c-MYC (8q24) genes and 7, 8, X chromosomes was evaluated.


RESULTS
Chromosomes 7, 8, X aneusomy was demonstrated in 91.5%, 78.3%, and 51.9% of the samples, respectively, whereas LPL deletion and MYC amplification were found in 76.0% and 1.6%. A genetic profile was considered as unfavorable when at least two aneusomic chromosomes and one altered gene were present. Tumors with an adverse genetic profile were more frequently present in patients with higher stages (P = 0.02), biochemical/clinical progression (P = 0.03), and Gleason grade 4 + 3 (P = 0.02). Multiple correspondence analysis identified one tumor group characterized by chromosome 8 aneusomy, X polysomy, LPL gene deletion, Gleason > 7 and 4 + 3 associated with progression.


CONCLUSIONS
In this study, we recognized the predictive power of previously identified cytogenetic profiles. Assessment of genetic set may characterize each patient and have influence on postoperative therapeutic strategies.
Department of Urology, Regina Elena Cancer Institute, Rome, Italy.
Michele
M
Gallucci
Roberta
R
Merola
Costantino
C
Leonardo
Piero
P
De Carli
Antonella
A
Farsetti
Steno
S
Sentinelli
Isabella
I
Sperduti
Marcella
M
Mottolese
Paolo
P
Carlini
Erika
E
Vico
Giuseppe
G
Simone
Annamaria
A
Cianciulli
D014408:Biomarkers, Tumor / Q000235:genetics*; D002869:Chromosome Aberrations; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D041321:Chromosomes, Human, X / Q000235:genetics; D018450:Disease Progression; D018628:Gene Dosage; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008071:Lipoprotein Lipase / Q000235:genetics; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology*; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D016271:Proto-Oncogene Proteins c-myc; D008071:Lipoprotein Lipase; D017430:Prostate-Specific Antigen